TSXV:TRL.H - Post by User
Post by
adri050on Sep 14, 2019 3:33pm
395 Views
Post# 30127293
Mackie research finally new update on Acerus
Mackie research finally new update on Acerus
https://www.cantechletter.com/2019/08/acerus-pharmaceuticals-has-a-270-per-cent-upside-says-mackie-research/
The analyst is calling for fiscal 2019 revenue and fully diluted EPS of $8.8 million and negative $0.05 per share, respectively, and fiscal 2020 revenue and fully diluted EPS of $21.0 million and negative $0.03 per share, respectively. Uddin expects ASP to be EPS-positive in 2021.
Uddin’s $0.50 target represented a projected 12-month return of 270 per cent